The stock has done great recently. It has appreciated by 328% on ytd basis, and is six times the 52 week low made a few months ago. Even on a 52 week basis it is up by 150%, though it has corrected from the high made recently. There have been several articles highlighting the investments made by Dr. Phillip Frost. One article on seekingalpha has recommended to buy NIMU mainly because of the potential of its product and possible interest by OPKO Health (OPK), another company where Dr. Frost has significant stake. Several of the stocks owned by Dr. Frost have done well recently. He purchased a significant number of NIMU shares at average price of $0.05 in April. Dr. Frost is known to be an astute investor with the ability to identify long term growth stories. He attempts to explore synergies between the various companies where he has a stake. For example, he has substantial stake in Biozone (BZNE) which owns a high potential drug delivery technology (QuSomes). There is an agreement between Biozone and OPKO Health (OPK) for testing of the QuSomes technology. The author believes that even NIMU can be part of a larger, long-term strategy which Dr. Frost is pursuing. Dr. Frost may be interested in the company because the products would complement and diversify OPKO's business. All this may be guesswork right now, but the possibility cannot be ruled out totally. However, the financials of NIMU are nothing great to say the least. Revenues are negligible, and improvement in financials is mandatory to justify the recent jump in the market cap. There can be corrections, though the support of Dr. Frost provides some assurance about future possibilities. Still, caution is required because this is a high risk – high reward bet.